Filtered By:
Therapy: Statin Therapy
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 11974 results found since Jan 2013.
Aggressive LDL-C Lowering and the Brain: Impact on Risk for Dementia and Hemorrhagic Stroke: A Scientific Statement From the American Heart Association
The objective of this scientific statement is to evaluate contemporary evidence that either supports or refutes the conclusion that aggressive low-density lipoprotein cholesterol lowering or lipid lowering exerts toxic effects on the brain, leading to cognitive impairment or dementia or hemorrhagic stroke. The writing group used literature reviews, references to published clinical and epidemiology studies, clinical and public health guidelines, authoritative statements, and expert opinion to summarize existing evidence and to identify gaps in current knowledge. Although some retrospective, case control, and prospective lon...
Source: Arteriosclerosis, Thrombosis and Vascular Biology - September 14, 2023 Category: Cardiology Authors: Larry B Goldstein Peter P Toth Jennifer L Dearborn-Tomazos Robert P Giugliano Benjamin J Hirsh Jessica M Pe ña Magdy H Selim Daniel Woo American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Source Type: research
Rosuvastatin effects on the HDL proteome in hyperlipidemic patients
Acta Pharm. 2023 Sep 14;73(3):363-384. doi: 10.2478/acph-2023-0034. Print 2023 Sep 1.ABSTRACTThe advancements in proteomics have provided a better understanding of the functionality of apolipoproteins and lipoprotein-associated proteins, with the HDL lipoprotein fraction being the most studied. The focus of this study was to evaluate the HDL proteome in dyslipidemic subjects without an established cardiovascular disease, as well as to test whether rosuvastatin treatment alters the HDL proteome. Patients with primary hypercholesterolemia or mixed dyslipidemia were assigned to 20 mg/day rosuvastatin and blood samples were dr...
Source: Acta Pharmaceutica - September 14, 2023 Category: Drugs & Pharmacology Authors: Ana Vavlukis Kristina Mladenovska Katarina Davalieva Marija Vavlukis Aleksandar Dimovski Source Type: research
New Targets in Atherosclerosis: Vascular Smooth Muscle Cell Plasticity and Macrophage Polarity
Clin Ther. 2023 Sep 12:S0149-2918(23)00319-3. doi: 10.1016/j.clinthera.2023.08.015. Online ahead of print.ABSTRACTPURPOSE: Despite an increase in treatment options, and substantial reductions in cardiovascular mortality over the past half-century, atherosclerosis remains the most prevalent cause of premature mortality worldwide. The development of innovative new therapies is crucial to further minimize atherosclerosis-related deaths. The diverse array of cell phenotypes derived from vascular smooth muscle cells (SMCs) and macrophages within atherosclerotic plaques are increasingly becoming recognized for their beneficial a...
Source: Clinical Therapeutics - September 14, 2023 Category: Drugs & Pharmacology Authors: Michael Hutton Madeleine Frazer Alexander Lin Sanjay Patel Ashish Misra Source Type: research
Rosuvastatin effects on the HDL proteome in hyperlipidemic patients
Acta Pharm. 2023 Sep 14;73(3):363-384. doi: 10.2478/acph-2023-0034. Print 2023 Sep 1.ABSTRACTThe advancements in proteomics have provided a better understanding of the functionality of apolipoproteins and lipoprotein-associated proteins, with the HDL lipoprotein fraction being the most studied. The focus of this study was to evaluate the HDL proteome in dyslipidemic subjects without an established cardiovascular disease, as well as to test whether rosuvastatin treatment alters the HDL proteome. Patients with primary hypercholesterolemia or mixed dyslipidemia were assigned to 20 mg/day rosuvastatin and blood samples were dr...
Source: Acta Pharmaceutica - September 14, 2023 Category: Drugs & Pharmacology Authors: Ana Vavlukis Kristina Mladenovska Katarina Davalieva Marija Vavlukis Aleksandar Dimovski Source Type: research
Aggressive LDL-C Lowering and the Brain: Impact on Risk for Dementia and Hemorrhagic Stroke: A Scientific Statement From the American Heart Association
The objective of this scientific statement is to evaluate contemporary evidence that either supports or refutes the conclusion that aggressive low-density lipoprotein cholesterol lowering or lipid lowering exerts toxic effects on the brain, leading to cognitive impairment or dementia or hemorrhagic stroke. The writing group used literature reviews, references to published clinical and epidemiology studies, clinical and public health guidelines, authoritative statements, and expert opinion to summarize existing evidence and to identify gaps in current knowledge. Although some retrospective, case control, and prospective lon...
Source: Arteriosclerosis, Thrombosis and Vascular Biology - September 14, 2023 Category: Cardiology Authors: Larry B Goldstein Peter P Toth Jennifer L Dearborn-Tomazos Robert P Giugliano Benjamin J Hirsh Jessica M Pe ña Magdy H Selim Daniel Woo American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Source Type: research
Rosuvastatin effects on the HDL proteome in hyperlipidemic patients
Acta Pharm. 2023 Sep 14;73(3):363-384. doi: 10.2478/acph-2023-0034. Print 2023 Sep 1.ABSTRACTThe advancements in proteomics have provided a better understanding of the functionality of apolipoproteins and lipoprotein-associated proteins, with the HDL lipoprotein fraction being the most studied. The focus of this study was to evaluate the HDL proteome in dyslipidemic subjects without an established cardiovascular disease, as well as to test whether rosuvastatin treatment alters the HDL proteome. Patients with primary hypercholesterolemia or mixed dyslipidemia were assigned to 20 mg/day rosuvastatin and blood samples were dr...
Source: Acta Pharmaceutica - September 14, 2023 Category: Drugs & Pharmacology Authors: Ana Vavlukis Kristina Mladenovska Katarina Davalieva Marija Vavlukis Aleksandar Dimovski Source Type: research
Aggressive LDL-C Lowering and the Brain: Impact on Risk for Dementia and Hemorrhagic Stroke: A Scientific Statement From the American Heart Association
The objective of this scientific statement is to evaluate contemporary evidence that either supports or refutes the conclusion that aggressive low-density lipoprotein cholesterol lowering or lipid lowering exerts toxic effects on the brain, leading to cognitive impairment or dementia or hemorrhagic stroke. The writing group used literature reviews, references to published clinical and epidemiology studies, clinical and public health guidelines, authoritative statements, and expert opinion to summarize existing evidence and to identify gaps in current knowledge. Although some retrospective, case control, and prospective lon...
Source: Arteriosclerosis, Thrombosis and Vascular Biology - September 14, 2023 Category: Cardiology Authors: Larry B Goldstein Peter P Toth Jennifer L Dearborn-Tomazos Robert P Giugliano Benjamin J Hirsh Jessica M Pe ña Magdy H Selim Daniel Woo American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Source Type: research
New Targets in Atherosclerosis: Vascular Smooth Muscle Cell Plasticity and Macrophage Polarity
Clin Ther. 2023 Sep 12:S0149-2918(23)00319-3. doi: 10.1016/j.clinthera.2023.08.015. Online ahead of print.ABSTRACTPURPOSE: Despite an increase in treatment options, and substantial reductions in cardiovascular mortality over the past half-century, atherosclerosis remains the most prevalent cause of premature mortality worldwide. The development of innovative new therapies is crucial to further minimize atherosclerosis-related deaths. The diverse array of cell phenotypes derived from vascular smooth muscle cells (SMCs) and macrophages within atherosclerotic plaques are increasingly becoming recognized for their beneficial a...
Source: Clinical Therapeutics - September 14, 2023 Category: Drugs & Pharmacology Authors: Michael Hutton Madeleine Frazer Alexander Lin Sanjay Patel Ashish Misra Source Type: research
Variability in Plasma Lipids Between Intensive Statin Therapy and Conventional-Dose Statins Combined with Ezetimibe Therapy in Patients with Coronary Atherosclerosis Disease
In this study, we aimed to examine the variability in plasma lipids under two different lipid-lowering regimens (intensive statin therapy versus the combination of conventional-dose statins with ezetimibe). In total, we have retrospectively examined 1275 patients with CAD from January 2009 to April 2019 and divided them into two groups: intensive statin group and conventional-dose statins combined with ezetimibe group. All patients were followed up for at least 1 year. Lipid variability was verified by standard deviation (SD), coefficient of variation (CV), and variability independent of mean (VIM) triple methods. Multiple...
Source: Atherosclerosis - September 13, 2023 Category: Cardiology Authors: Jinhua Jin Liwen Shan Manjun Wang Lu Liu Tian Xu Duanbin Li Zhezhe Chen Xianglan Liu Wenbin Zhang Ya Li Source Type: research
Association of Coronary Artery Calcium Detected by Routine Ungated CT Imaging With Cardiovascular Outcomes
CONCLUSIONS: Incidental CAC ≥100 was associated with an increased risk of all-cause death and adverse cardiovascular outcomes, beyond traditional risk factors. DL-CAC from routine non-ECG-gated CTs identifies patients at increased cardiovascular risk and holds promise as a tool for opportunistic screening to facilitate earlier intervention.PMID:37704309 | DOI:10.1016/j.jacc.2023.06.040
Source: Atherosclerosis - September 13, 2023 Category: Cardiology Authors: Allison W Peng Ramzi Dudum Sneha S Jain David J Maron Bhavik N Patel Nishith Khandwala David Eng Akshay S Chaudhari Alexander T Sandhu Fatima Rodriguez Source Type: research
